27.41 -17.22 (-57.69%)
AZN
Stock Details
Last Trade:27.41 Change:-17.22 (-57.69%) Prev Close:44.63 Open: 29.85 Days Range:25.00 – 29.98 52 Week Range: 29.96 - 49.85 Volume:441989 P/E: N/AEPS:0.00
View AllRecent Alerts 07/03/09
Recent Alert on 06/15/09 at 9:46am
David Moenning's Daily State of the Markets: 6/15
David Moenning's Daily State of the Markets: 6/15
Back In The Black Although stocks finished in the green on Friday and the DJIA finally made it back into the black for the year, it would appear that the now three-month old rally has been put on hold. While there was some good news to be found –... Read More
Recent Alert on 06/08/09 at 8:31am
Results from Bristol Myers' (BMY), AstraZeneca's (AZN) dapagliflozin and ONGLYZA(TM) Studies Presented at ADA
Results from Bristol Myers' (BMY), AstraZeneca's (AZN) dapagliflozin and ONGLYZA(TM) Studies Presented at ADA
Recent Alert on 06/04/09 at 10:06am
Abbott (ABT) and AstraZeneca (AZN) Submit New Drug Application to the FDA for CERTRIAD
Abbott (ABT) and AstraZeneca (AZN) Submit New Drug Application to the FDA for CERTRIAD
Recent Alert on 06/04/09 at 10:06am
Abbott (ABT) and AstraZeneca (AZN) Submit New Drug Application to the FDA for CERTRIAD
Abbott (ABT) and AstraZeneca (AZN) Submit New Drug Application to the FDA for CERTRIAD
View AllRecent Press Releases
Press Release on 07/01/09 at 7:00am
Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community
Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community
Press Release on 06/30/09 at 9:00am
New Expanded Atlantis(TM) Patient-Specific Abutment Compatibility and Material Option for Straumann Implants
New Expanded Atlantis(TM) Patient-Specific Abutment Compatibility and Material Option for Straumann Implants
Press Release on 06/29/09 at 12:19pm
MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
Press Release on 06/29/09 at 12:19pm
MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
Press Release on 06/29/09 at 12:19pm
MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 07/01/09 at 4:48am
FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG
FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG
Blog Posts on 06/29/09 at 3:38am
Cramer's Lightning Round - The Only Solar Stock Worth Buying (6/26/09)
Cramer's Lightning Round - The Only Solar Stock Worth Buying (6/26/09)
Blog Posts on 06/28/09 at 7:47am
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch